The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Pulmonary Embolism Drug Market Research Report 2025
Synopsis
The global Pulmonary Embolism Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Pulmonary Embolism Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pulmonary Embolism Drug.
Report Scope
The Pulmonary Embolism Drug market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pulmonary Embolism Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pulmonary Embolism Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Accu-Break Pharmaceuticals, Inc.
Dong-A Socio Holdings Co. Ltd.
F. Hoffmann-La Roche Ltd.
Genentech, Inc.
Verseon Corp
Segment by Type
DS-9231
DS-1040
TRX-1
Others
Segment by Application
Hospital
Clinic
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Pulmonary Embolism Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Pulmonary Embolism Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global Pulmonary Embolism Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Pulmonary Embolism Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pulmonary Embolism Drug.
Report Scope
The Pulmonary Embolism Drug market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pulmonary Embolism Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pulmonary Embolism Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Accu-Break Pharmaceuticals, Inc.
Dong-A Socio Holdings Co. Ltd.
F. Hoffmann-La Roche Ltd.
Genentech, Inc.
Verseon Corp
Segment by Type
DS-9231
DS-1040
TRX-1
Others
Segment by Application
Hospital
Clinic
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Pulmonary Embolism Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Pulmonary Embolism Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Pulmonary Embolism Drug Market Overview
1.1 Product Overview and Scope of Pulmonary Embolism Drug
1.2 Pulmonary Embolism Drug Segment by Type
1.2.1 Global Pulmonary Embolism Drug Market Value Comparison by Type (2024-2030)
1.2.2 DS-9231
1.2.3 DS-1040
1.2.4 TRX-1
1.2.5 Others
1.3 Pulmonary Embolism Drug Segment by Application
1.3.1 Global Pulmonary Embolism Drug Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Pulmonary Embolism Drug Market Size Estimates and Forecasts
1.4.1 Global Pulmonary Embolism Drug Revenue 2019-2030
1.4.2 Global Pulmonary Embolism Drug Sales 2019-2030
1.4.3 Global Pulmonary Embolism Drug Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Pulmonary Embolism Drug Market Competition by Manufacturers
2.1 Global Pulmonary Embolism Drug Sales Market Share by Manufacturers (2019-2024)
2.2 Global Pulmonary Embolism Drug Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Pulmonary Embolism Drug Average Price by Manufacturers (2019-2024)
2.4 Global Pulmonary Embolism Drug Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Pulmonary Embolism Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Pulmonary Embolism Drug, Product Type & Application
2.7 Pulmonary Embolism Drug Market Competitive Situation and Trends
2.7.1 Pulmonary Embolism Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Pulmonary Embolism Drug Players Market Share by Revenue
2.7.3 Global Pulmonary Embolism Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Pulmonary Embolism Drug Retrospective Market Scenario by Region
3.1 Global Pulmonary Embolism Drug Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Pulmonary Embolism Drug Global Pulmonary Embolism Drug Sales by Region: 2019-2030
3.2.1 Global Pulmonary Embolism Drug Sales by Region: 2019-2024
3.2.2 Global Pulmonary Embolism Drug Sales by Region: 2025-2030
3.3 Global Pulmonary Embolism Drug Global Pulmonary Embolism Drug Revenue by Region: 2019-2030
3.3.1 Global Pulmonary Embolism Drug Revenue by Region: 2019-2024
3.3.2 Global Pulmonary Embolism Drug Revenue by Region: 2025-2030
3.4 North America Pulmonary Embolism Drug Market Facts & Figures by Country
3.4.1 North America Pulmonary Embolism Drug Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Pulmonary Embolism Drug Sales by Country (2019-2030)
3.4.3 North America Pulmonary Embolism Drug Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Pulmonary Embolism Drug Market Facts & Figures by Country
3.5.1 Europe Pulmonary Embolism Drug Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Pulmonary Embolism Drug Sales by Country (2019-2030)
3.5.3 Europe Pulmonary Embolism Drug Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Pulmonary Embolism Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Pulmonary Embolism Drug Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Pulmonary Embolism Drug Sales by Country (2019-2030)
3.6.3 Asia Pacific Pulmonary Embolism Drug Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Pulmonary Embolism Drug Market Facts & Figures by Country
3.7.1 Latin America Pulmonary Embolism Drug Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Pulmonary Embolism Drug Sales by Country (2019-2030)
3.7.3 Latin America Pulmonary Embolism Drug Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Pulmonary Embolism Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Pulmonary Embolism Drug Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Pulmonary Embolism Drug Sales by Country (2019-2030)
3.8.3 Middle East and Africa Pulmonary Embolism Drug Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Pulmonary Embolism Drug Sales by Type (2019-2030)
4.1.1 Global Pulmonary Embolism Drug Sales by Type (2019-2024)
4.1.2 Global Pulmonary Embolism Drug Sales by Type (2025-2030)
4.1.3 Global Pulmonary Embolism Drug Sales Market Share by Type (2019-2030)
4.2 Global Pulmonary Embolism Drug Revenue by Type (2019-2030)
4.2.1 Global Pulmonary Embolism Drug Revenue by Type (2019-2024)
4.2.2 Global Pulmonary Embolism Drug Revenue by Type (2025-2030)
4.2.3 Global Pulmonary Embolism Drug Revenue Market Share by Type (2019-2030)
4.3 Global Pulmonary Embolism Drug Price by Type (2019-2030)
5 Segment by Application
5.1 Global Pulmonary Embolism Drug Sales by Application (2019-2030)
5.1.1 Global Pulmonary Embolism Drug Sales by Application (2019-2024)
5.1.2 Global Pulmonary Embolism Drug Sales by Application (2025-2030)
5.1.3 Global Pulmonary Embolism Drug Sales Market Share by Application (2019-2030)
5.2 Global Pulmonary Embolism Drug Revenue by Application (2019-2030)
5.2.1 Global Pulmonary Embolism Drug Revenue by Application (2019-2024)
5.2.2 Global Pulmonary Embolism Drug Revenue by Application (2025-2030)
5.2.3 Global Pulmonary Embolism Drug Revenue Market Share by Application (2019-2030)
5.3 Global Pulmonary Embolism Drug Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Accu-Break Pharmaceuticals, Inc.
6.1.1 Accu-Break Pharmaceuticals, Inc. Corporation Information
6.1.2 Accu-Break Pharmaceuticals, Inc. Description and Business Overview
6.1.3 Accu-Break Pharmaceuticals, Inc. Pulmonary Embolism Drug Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Accu-Break Pharmaceuticals, Inc. Pulmonary Embolism Drug Product Portfolio
6.1.5 Accu-Break Pharmaceuticals, Inc. Recent Developments/Updates
6.2 Dong-A Socio Holdings Co. Ltd.
6.2.1 Dong-A Socio Holdings Co. Ltd. Corporation Information
6.2.2 Dong-A Socio Holdings Co. Ltd. Description and Business Overview
6.2.3 Dong-A Socio Holdings Co. Ltd. Pulmonary Embolism Drug Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Dong-A Socio Holdings Co. Ltd. Pulmonary Embolism Drug Product Portfolio
6.2.5 Dong-A Socio Holdings Co. Ltd. Recent Developments/Updates
6.3 F. Hoffmann-La Roche Ltd.
6.3.1 F. Hoffmann-La Roche Ltd. Corporation Information
6.3.2 F. Hoffmann-La Roche Ltd. Description and Business Overview
6.3.3 F. Hoffmann-La Roche Ltd. Pulmonary Embolism Drug Sales, Revenue and Gross Margin (2019-2024)
6.3.4 F. Hoffmann-La Roche Ltd. Pulmonary Embolism Drug Product Portfolio
6.3.5 F. Hoffmann-La Roche Ltd. Recent Developments/Updates
6.4 Genentech, Inc.
6.4.1 Genentech, Inc. Corporation Information
6.4.2 Genentech, Inc. Description and Business Overview
6.4.3 Genentech, Inc. Pulmonary Embolism Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Genentech, Inc. Pulmonary Embolism Drug Product Portfolio
6.4.5 Genentech, Inc. Recent Developments/Updates
6.5 Verseon Corp
6.5.1 Verseon Corp Corporation Information
6.5.2 Verseon Corp Description and Business Overview
6.5.3 Verseon Corp Pulmonary Embolism Drug Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Verseon Corp Pulmonary Embolism Drug Product Portfolio
6.5.5 Verseon Corp Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Pulmonary Embolism Drug Industry Chain Analysis
7.2 Pulmonary Embolism Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Pulmonary Embolism Drug Production Mode & Process
7.4 Pulmonary Embolism Drug Sales and Marketing
7.4.1 Pulmonary Embolism Drug Sales Channels
7.4.2 Pulmonary Embolism Drug Distributors
7.5 Pulmonary Embolism Drug Customers
8 Pulmonary Embolism Drug Market Dynamics
8.1 Pulmonary Embolism Drug Industry Trends
8.2 Pulmonary Embolism Drug Market Drivers
8.3 Pulmonary Embolism Drug Market Challenges
8.4 Pulmonary Embolism Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
